Document is current
Any future updates will be listed below
-
Authors
Ondrejcak, Tomas
Hu, Neng-Wei
Coode, Emily
Campbell, Tom
Corbett, Grant T.
Doykov, Ivan
Mills, Kevin
Walsh, Dominic M.
Livesey, Frederick J.
Rowan, Michael J.
Klyubin, Igor
-
Funding
Funding for this research was provided by:
Science Foundation Ireland (19/FFP/6437)
University of Dublin, Trinity College
- License Information
-
More Information
Article History
Received: 7 February 2025
Revised: 2 May 2025
Accepted: 15 May 2025
First Online: 2 June 2025
Declarations
:
: EC, TC and FJL are all employees of Talisman Therapeutics. FJL is a founder and shareholder in Gen2 Neuroscience. D.M.W. is a former employee of and holds stock in Biogen, and he is also an advisor to Acumen, Apellis, BrainQr, Convergen and the Dementia Discovery Fund. The other authors declare that they have no competing interests.
: Human brain tissue was used in accordance with Trinity College Dublin Faculty of Health Science Ethics Committee (approval 16014) and Partners Institutional Review Board (protocol, Walsh BWH 2011) guidelines. This research was carried out in accordance with the UK Code of Practice for the Use of Human Stem Cell Lines. All animal experiments were conducted in accordance with ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines under the approval of Trinity College Dublin local animal research ethics committee and the Health Products Regulatory Authority in Ireland.
